Loading stock data…
$7.87-0.01 (-0.08%)
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. in the Healthcare sector is trading at $7.87 with a market capitalization of $639M. Wall Street consensus targets $26.54 (13 analysts), implying a +237.3% move over the next 12 months. The stock is currently near its 52-week low of $7.60, remaining 62.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$63.55M↑ | -$64.50M↑ | -$83.38M↓ | -$31.50M↓ | -$30.66M |
| Net Income | -$60.19M↑ | -$60.67M↑ | -$79.55M↓ | -$29.42M↑ | -$29.84M |
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarini...